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Abstract
The anti-Parkinsonian effect of glutamate metabotropic
group 5 (mGluR5) and adenosine A2A receptor antagonists is
believed to result from their ability to postsynaptically control
the responsiveness of the indirect pathway that is hyper-
functioning in Parkinson’s disease. mGluR5 and A2A antago-
nists are also neuroprotective in brain injury models involving
glutamate excitotoxicity. Thus, we hypothesized that the anti-
Parkinsonian and neuroprotective effects of A2A and mGluR5
receptors might be related to their control of striatal glutamate
release that actually triggers the indirect pathway. The A2A
agonist, CGS21680 (1–30 nM) facilitated glutamate release
from striatal nerve terminals up to 57%, an effect prevented by
the A2A antagonist, SCH58261 (50 nM). The mGluR5 agonist,
CHPG (300–600 lM) also facilitated glutamate release up to
29%, an effect prevented by the mGluR5 antagonist, MPEP
(10 lM). Both mGluR5 and A2A receptors were located in the
active zone and 57 ± 6% of striatal glutamatergic nerve ter-
minals possessed both A2A and mGluR5 receptors, suggest-
ing a presynaptic functional interaction. Indeed, submaximal
concentrations of CGS21680 (1 nM) and CHPG (100 lM)
synergistically facilitated glutamate release and the facilitation
of glutamate release by 10 nM CGS21680 was prevented by
10 lM MPEP, whereas facilitation by 300 lM CHPG was
prevented by 10 nM SCH58261. These results provide the first
direct evidence that A2A and mGluR5 receptors are co-located
in more than half of the striatal glutamatergic terminals where
they facilitate glutamate release in a synergistic manner. This
emphasizes the role of the modulation of glutamate release as
a likely mechanism of action of these receptors both in striatal
neuroprotection and in Parkinson’s disease.
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The role of the striatum in the control of motor function is
essentially viewed as a balanced activation of its two main
pathways, the direct and indirect pathways that cause
opposite control of thalamic relays, which then impinge on
the motor cortex (Obeso et al. 2000). These two main striatal
pathways are both constituted by medial spiny GABAergic
neurons and are both triggered by cortico-thalamic glutamat-
ergic fibres (Calabresi et al. 1996). These two pathways are
modulated in an opposite manner by important modulators of
locomotion, mainly dopamine and also adenosine. Thus,
medial spiny neurons of the indirect pathway are endowed
with inhibitory dopamine D2 and facilitatory adenosine A2A
receptors, whereas the medial spiny neurons of the direct
pathway are endowed with facilitatory D1 receptors and
inhibitory A1 receptors (Svenningsson et al. 1999). Dopam-
ine is considered the chief modulator of the balanced
activation of striatal pathways. Thus, in Parkinson’s disease,
the most common basal ganglia motor dysfunction, there is a
severe decrease of striatal dopamine levels that causes a
hyperactivation of the indirect pathway (Obeso et al. 2000).
As facilitatory A2A receptors are selectively located in
neurons of the indirect pathway, antagonists of A2A receptors
have been developed as anti-parkinsonian drugs (Schwarzs-
child et al. 2002). Furthermore, it is now recognised that the
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control of the responsiveness of the medial spiny neurons of
the indirect pathway depends not only on D2 and A2A
receptors but also on metabotropic glutamate receptors of the
subtype 5 (mGluR5), which form a trimeric complex to
control the responsiveness of medial spiny neurons of the
indirect pathway (Ferre´ et al. 2003). And, as occurs with
antagonists of A2A receptors (Schwarzschild et al. 2002),
antagonists of mGluR5 receptors also display anti-parkinso-
nian properties (Ossowska et al. 2001; Breysse et al. 2002).
Interestingly, antagonists of either A2A (Fredholm et al.
2003) or mGluR5 receptors (Bruno et al. 2000; Battaglia
et al. 2002) are also neuroprotective in different models of
brain injury that involve glutamate excitotoxicity. However,
it is not clear if this neuroprotective effect is associated with
the ability of A2A and mGluR5 receptors to control glutamate
release, a key event in different neurological disorders
(Lipton and Rosenberg 1994). And if these two receptors
would control glutamate release, it could be hypothesised
that the anti-parkinsonian effects of A2A or mGluR5 recep-
tors antagonists might not only be because of their ability to
control the responsiveness of neurons of the indirect pathway
but also to their ability to control the release of glutamate that
is actually the trigger of striatal pathways (Calabresi et al.
1996). One fundamental issue that needs to be demonstrated
to entertain this hypothesis is to show if A2A and mGluR5
receptors are indeed located in glutamatergic nerve terminals
impinging in the striatum and if they facilitate glutamate
release.
As our interest is to focus on the possible presynaptic
location of A2A and mGluR5 receptors, we chose the most
adequate experimental model to study presynaptic phenom-
ena, i.e. purified nerve terminals or synaptosomes (Cunha
1998), which rule out possible confounding effects intrinsic
to experimental manipulation where the striatal circuitry is
preserved like electrophysiological recordings in striatal
slices or microdialysis in living animals (Corsi et al. 2000,
2003). This allowed us to conclude that both A2A and
mGluR5 receptors are actually co-located in nearly half of
the glutamatergic nerve terminals in the rat striatum where
they facilitate the evoked release of glutamate, operating in a
synergistic manner.
Materials and methods
Male Wistar rats (6–8 weeks old, 140–160 g, obtained from Harlan
Ibe´rica, Barcelona, Spain) were used throughout this study and were
handled according with the EU guidelines for use of experimental
animals, the rats being anaesthesized under halothane atmosphere
before being killed by decapitation.
[3H]glutamate release studies
The release of [3H]glutamate from rat striatal nerve terminals was
performed as previously described (Lopes et al. 2002). The nerve
terminals were prepared using a combined sucrose/Percoll
centrifugation protocol and were re-suspended in oxygenated Krebs
solution of the following composition (in mM): NaCl 124, KCl 3,
NaH2PO4 1.25, NaHCO3 25, MgSO4 2, CaCl2 2 and glucose 10,
which was gassed with a 95% O2 and 5% CO2 mixture. The nerve
terminals were equilibrated at 37C for 10 min, loaded with
[3H]glutamate (0.2 lM) for 5 min at 37C, washed, layered over
Whatman GF/C filters and superfused (flow rate: 0.8 mL/min) with
Krebs solution for 20 min before starting collection of the superfu-
sate. The synaptosomes were stimulated with 20 mM K+ at 3 and
9 min after starting sample collection (S1 and S2), triggering a release
of tritium that was found to be mostly [3H]glutamate, released in a
Ca2+-dependent manner (Lopes et al. 2002). Tested agonists were
added 2 min before S2 onwards, whereas antagonists were added
from 10 min before starting sample collection onwards. Radioactiv-
ity was expressed in terms of disintegrations per second per
milligram of protein (Bq/mg) in each chamber (Lopes et al. 2002).
Western blot analysis in subsynaptic fractions
The relative mGluR5 and A2A receptor immunoreactivity was
evaluated by western blot analysis, as previously described (Rebola
et al. 2003a) using antibodies against either adenosine A2A receptor
(1 : 500 dilution) or mGluR5 receptors (1 : 3000 dilution). This
analysis was carried out in the purified presynaptic and postsynaptic
components of the active zone as well as in the non-active zone
fraction of rat striatal nerve terminals, separated upon solubilization of
the synaptosomal fraction as initially described by Phillips et al.
(2001). We have previously confirmed that this subsynaptic fraction-
ation method allows an over 90% effective separation of active zone
(syntaxin and SNAP25), postsynaptic density (PSD95 and NMDA
receptor subunit 1) and extra-synaptic (synaptophysin) markers and
can be used to access the subsynaptic distribution of metabotropic
receptors (Rebola et al. 2003b).
Immunocytochemical analysis in nerve terminals
For immunochemical analysis, striatal synaptosomes were obtained
through a discontinuous Percoll gradient, as previously described
(Dia´z-Herna´ndez et al. 2002), with minor modifications. Striatal
tissue was homogenized in a medium containing 0.25 M sucrose and
5 mM TES (pH 7.4). The homogenate was spun for 3 min 2000 g at
4C and the supernatant spun again at 9500 g for 13 min. Then, the
pellets were re-suspended in 8 mL of 0.25 M sucrose and 5 mM TES
(pH 7.4) and 2 mL were placed onto 3 mL of Percoll discontinuous
gradients containing 0.32 M sucrose, 1 mM EDTA, 0.25 mM
dithiothreitol and 3, 10, or 23% Percoll, pH 7.4. The gradients
were centrifuged at 25 000 g for 11 min at 4C. Synaptosomes were
collected between the 10 and 23% Percoll bands and diluted in
15 mL of HEPES buffered medium (140 mM NaCl, 5 mM KCl,
5 mM NaHCO3, 1.2 mM NaH2PO4, 1 mM MgCl2, 10 mM glucose,
and 10 mM HEPES, pH 7.4). After centrifugation at 22 000 g for
11 min at 4C, the synaptosomal pellet was removed. This
procedure for preparation of the synaptosomes (in the absence of
calcium) is crucial to allow reducing the amount of postsynaptic
density material. In fact, immunocytochemical analysis of the
synaptosomes obtained with this discontinuous Percoll gradient
showed that less than 3% of the synaptophysin-positive elements
were labelled by an anti-PSD-95 antibody (data not shown).
These striatal synaptosomes were placed onto cover-slips previ-
ously coated with poly L-lisine, fixed with 4% paraformaldehyde for
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15 min and washed twice with phosphate-buffered saline (PBS)
medium (140 mM NaCl, 3 mM KCl, 20 mM NaH2PO4, 15 mM
KH2PO4, pH 7.4). The synaptosomes were permeabilized in PBS
with 0.2% Triton X-100 for 10 min and then blocked for 1 h in PBS
with 3% bovine serum albumin (BSA) and 5% normal rat serum. The
synaptosomes were then washed twice with PBS and incubated with
goat anti-A2A receptor (1 : 500), guinea pig anti-vGluT1 (1 : 5000)
and guinea pig anti-vGluT2 (1 : 5000), together with rabbit anti-
mGluR5 (1 : 1000) or mouse anti-synaptophysin (1 : 200) for 1 h at
23–25C. It should be emphasized that anti-vGluT1 and anti-vGluT2
were applied together to identify the population of rat striatal
glutamatergic nerve terminals. The synaptosomes were then washed
three times with PBS with 3% BSA and incubated for 1 h at room
temperature with AlexaFluor-488 (green) labelled donkey anti-goat
IgG antibody, AlexaFluor-598 (red) labelled goat anti-guinea pig IgG
and AlexaFluor-350 (blue) labelled goat anti-rabbit or goat anti-
mouse IgG antibodies (1 : 200 for all). To avoid recognition of the
goat anti-guinea pig, goat anti-rabbit and goat anti-mouse antibodies
by the donkey anti-goat antibody, first we applied the donkey anti-
goat and, after washing with PBS, we applied the other secondary
antibodies. After washing and mounting onto slides with Prolong
Antifade, the preparations were visualized in a Zeiss Axiovert 200
inverted fluorescence microscope equipped with a cooled CCD
camera and analysed with MetaFluor 4.0 software. Each cover-slip
was analyzed by counting three different fields and in each field a
total amount of 100 individualized elements.
Statistics
The values are mean ± SEM of n experiments. To test the
significance of the effect of a drug versus control, a paired Student’s
t-test was used. When making comparisons from different set of
experiments with control, one-way variance analysis (ANOVA) was
used, followed by Dunnett’s test. p £ 0.05 was considered to
represent a significant difference.
Reagents
2-[4-(2-p-carboxyethyl)phenylamino]-5¢-N-ethylcarboxamidoadeno-
sine (CGS 21680) and 1,3-dipropyl-8-cyclopentyladenosine
(DPCPX) were from Research Biochemicals (Reagente 5, Oporto,
Portugal), 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-
1,2,4-triazolo[1,5-c]pyrimidine (SCH 58261) was a kind gift of
Scott Weiss (Vernalis, UK) (RS)-2-chloro-5-hydroxyphenylglycine
(CHPG) and 2-methyl-6-phenylethylnyl)pyridine (MPEP) were
from Tocris (Avonmouth, UK), [3H]glutamate (specific activity
45 Ci/mmol) was from Amersham (Buckinghamshire, UK), goat
purified IgG anti-adenosine A2A receptor antibody (200 lg/mL) was
from Santa Cruz Biotechnology-Europe (Freelab, Lisbon, Portugal),
rabbit purified IgG anti-mGluR5 receptor antibody (100 lg in
232 lL of 0.2 M Tris/glycine buffer, pH 7.5, with 0.15 M NaCl) was
from Upstate (Reagente 5, Oporto, Portugal), guinea pig anti-
vesicular glutamate transporter type 1 and guinea pig anti-vesicular
glutamate transporter type 2 were from Chemicon (Hofheim,
Germany), mouse anti-synaptophysin (100 lg in 200 lL water)
was from Sigma (Sintra, Portugal) and mouse anti-PSD-95 was from
Upstate Biotechnology (Lake Placid, NY, USA). All other reagents
were of the highest purity available.
CGS 21680 and SCH 58261 were made up as 5-mM stock
solutions in dimethylsulfoxide, DPCPX was made up as a 5-mM
stock in 99% dimethylsulfoxide and 1% NaOH 1 M and MPEP was
made up as a 5-M stock in 100 mM NaOH. All drug stock solutions
were diluted directly into the superfusion solution to the appropriate
final concentration and the pH corrected to pH 7.4 when required.
Dimethylsulfoxide, in the maximal concentration used, was devoid
of effects on [3H]glutamate release.
Results
Modulation of glutamate release by A2A and mGluR5
receptors
The evoked release of tritium, triggered by 20 mM K+ for
30 s, from superfused nerve terminals previously labelled
with [3H]glutamate was essentially constituted by [3H]glu-
tamate that is released in a Ca2+-dependent manner (Lopes
et al. 2002), suggesting that it may represent a vesicular
release of glutamate.
The presence of the selective A2A receptor agonist,
CGS 21680 (1–30 nM), facilitated in a concentration-depend-
ent manner the evoked release of glutamate from striatal
nerve terminals (Fig. 1). In fact, 1 nM CGS 21680 facilitated
the evoked release of glutamate by 20.8 ± 8.5% (n ¼ 6),
10 nM CGS 2160 caused a 57.1 ± 9.8% (n ¼ 5) facilitation
and 30 nM CGS 21680 caused a 50.4 ± 9.0% (n ¼ 6)
facilitation. This facilitatory effect of 10 nM CGS 21680
was prevented by the selective A2A receptor antagonist,
SCH 58261 (50 nM, n ¼ 5), but not significantly (p > 0.05)
modified by the selective A1 receptor antagonist, DPCPX
(50 nM, n ¼ 4). This indicates that the facilitatory effect of
CGS 21680 on the evoked release of glutamate from striatal
nerve terminals is mediated by A2A receptors and is
independent of A1 receptor modulation, in contrast to what
was reported in glutamatergic nerve terminals of the rat
hippocampus (Lopes et al. 2002). It should be noted that
neither SCH 58261 nor DPCPX caused any effect per se on
the evoked release of glutamate, in accordance with the
inexistence of tonic effects of endogenously released mod-
ulators in superfused synaptosomes because any released
substance is effectively washed out by superfusion (Raiteri
and Raiteri 2000).
The selective mGluR5 receptor agonist, CHPG (300–
600 lM), also facilitated the evoked release of glutamate
from striatal nerve terminals (Fig. 2). In fact, 300 lM CHPG
facilitated the evoked release of glutamate by 25.7 ± 6.4%
(n ¼ 6) and 600 lM CHPG caused a 28.8 ± 5.8% (n ¼ 6)
facilitation, whereas lower concentrations of CHPG (10–
100 lM) failed to significantly (p > 0.05) modify the evoked
release of glutamate. The facilitatory effect of 300 lM CHPG
was prevented by the selective mGluR5 receptor antagonist,
MPEP (10 lM, n ¼ 4), further confirming that the activation
of mGluR5 receptors facilitates the evoked release of
glutamate from striatal nerve terminals.
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Identification of A2A and mGluR5 receptors in
glutamatergic nerve terminals
The ability of both A2A and mGluR5 agonists to facilitate the
evoked release of glutamate allows us to predict that these
receptors should be located in the active zone of nerve
terminals. To confirm this, we used a recent method of
subsynaptic fractionation that allows separating the presy-
naptic active zone and postsynaptic density from other
presynaptic proteins not located in synapses (Phillips et al.
2001). We have previously validated this technique that
allows an over 90% efficiency of separation of these fractions
and we have confirmed its usefulness to evaluate the
subsynaptic distribution of adenosine receptors (Rebola et al.
2003b). As illustrated in Fig. 3, we found that A2A receptors
could be identified by western blot analysis in the presynap-
tic active zone fraction, albeit this receptor is most densely
located in the postsynaptic density fraction, as also conclu-
ded in electron microscopy studies carried out by others
(Hettinger et al. 2001). We also found that mGluR5 receptors
were located in the active zone (Fig. 3), although mGluR5
immunoreactivity was greater in the postsynaptic density
fraction, as also concluded in electron microscopy studies
carried out by others (Paquet and Smith 2003).
Because this fractionation procedure does not allow
separating nerve terminals releasing different types of
neurotransmitters, we undertook a complementary
immunocytochemistry approach aimed at defining whether
A2A and mGluR5 receptors immunoreactivity could be
detected in glutamatergic nerve terminals, identified with
the simultaneous use of antibodies against vesicular glutam-
ate transporters type 1 and 2 (vGluT1 and vGluT2). As
illustrated in Fig. 4(a), 45.5 ± 4.6% of the synaptophysin
immunoreactive elements were also endowed with A2A
receptor immunoreactivity and 52.1 ± 1.4% of the synapto-
physin immunoreactive elements were also endowed with
mGluR5 receptor immunoreactivity (n ¼ 3). In the general
population of striatal nerve terminals, identified as synapt-
ophysin-immunoreactive elements, we found a general co-
localization of A2A and mGluR5 immunoreactivity (Fig. 4).
In fact, 83.8 ± 8.9% (n ¼ 3) of A2A receptor-immunoposi-
tive nerve terminals were also labelled with the mGluR5
receptor antibody. Likewise, 90.0 ± 2.0% (n ¼ 5) of the
mGluR5 receptor-immunopositive nerve terminals were also
labelled with the A2A receptor antibody. However, glutamat-
ergic nerve terminals (vGluT1- and vGluT2-immunoreac-
tive) only represented 20.2 ± 1.6% (n ¼ 3) of striatal nerve
terminals, identified as synaptophysin-positive elements.
And, as illustrated in Fig. 4, triple labelling studies with
antibodies against A2A and mGluR5 receptors and against
vGluT1 and vGluT2 indicated that 57.4 ± 1.1% (n ¼ 4) of
the vGluT1 or -2 positive nerve terminals are equipped with
both A2A and mGluR5 receptors and few (< 6.8%) of
glutamatergic nerve terminals are equipped with only A2A
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Fig. 1 Concentration-dependent facilitation by the adenosine A2A
receptor agonist, CGS 21680, of the evoked release of [3H]glutamate
from rat striatal nerve terminals (a) and antagonism of this effect by a
selective A2A receptor antagonist, SCH 58261, but not by an A1
selective antagonist, DPCPX (b). Neither SCH 58261 (50 nM) nor
DPCPX (50 nM) modified the evoked release of glutamate by them-
selves (not shown). *p < 0.05 compared with 0% in (a) and with the
effect of CGS 21680 (30 nM, first bar from the left) in (b). The results
are mean ± SEM of four to six experiments.
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Fig. 2 Concentration-dependent facilitation by the metabotropic glu-
tamate receptor subtype 5 (mGluR5) agonist, CHPG, of the evoked
release of [3H]glutamate from rat striatal nerve terminals (a) and ant-
agonism of this effect by a selective mGluR5 antagonist, MPEP (b),
which was devoid of effects by itself (not shown). *p < 0.05 compared
with 0% in (a) and with the effect of CHPG (300 lM, first bar from the
left) in (b). The results are mean ± SEM of four to six experiments.
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receptors or mGluR5 receptors (Fig. 4). This directly shows
that A2A and mGluR5 receptors are located in glutamatergic
nerve terminals, but it also indicates that only about half of
the glutamatergic nerve terminals are equipped with these
two neuromodulatory systems. It should also be noted that
presynaptic A2A and mGluR5 receptors are not solely located
in glutamatergic nerve terminals in the striatum. In fact, only
27.8 ± 1.6% (n ¼ 4) of the A2A receptor immunoreactivity
is located in vGluT1 or vGluT2 immunoreactive nerve
terminals. Likewise, only 32.3 ± 1.5% (n ¼ 4) of the
mGluR5 receptor immunoreactivity is located in vGluT1 or
vGluT2 immunoreactive nerve terminals.
Functional interaction between presynaptic A2A and
mGluR5 receptors
As we found a near total co-localization of A2A and mGluR5
receptors in about 50% of the glutamatergic nerve terminals
of the rat striatum, and it was previously shown that there
was a synergy between postsynaptic A2A and mGluR5
receptors (Ferre´ et al. 2002; Nishi et al. 2003), we tested if
there was also an interaction between presynaptic A2A and
mGluR5 receptors in the control of glutamate release.
As illustrated in Fig. 5, we found that there was a
cross-inhibition by antagonists of these two modulatory
systems. In fact, the facilitation of the evoked release of
glutamate by the A2A receptor agonist, CGS 21680 (10 nM)
was prevented by the mGluR5 receptor antagonist, MPEP
(10 lM, n ¼ 4). Likewise, the facilitation of the evoked
release of glutamate by the mGluR5 receptor agonist, CHPG
(300 lM), was prevented by the A2A receptor antagonist
SCH 58261 (50 nM, n ¼ 4). This suggests a tight interaction
between these two presynaptic receptor systems in glutamat-
ergic nerve terminals.
To investigate if the activation of A2A and mGluR5
receptors caused a synergistic facilitation of the evoked
release of glutamate, we tested the effect of co-activation of
both A2A and mGluR5 receptors. When using submaximal
concentrations of each receptor agonist, we observed that the
co-administration of 1 nM CGS 21680, together with 100 lM
CHPG, caused a 44.3 ± 6.8% (n ¼ 9) facilitation of the
evoked release of glutamate (Fig. 5c). This facilitation is
greater (p < 0.05) than that obtained only with 1 nM
CGS 21680 (20.8 ± 8.5%, n ¼ 6) and represents a syner-
gistic effect as 100 lM CHPG did not significantly (p > 0.05)
modify the evoked release of glutamate. To further confirm
that there was a cross-dependency resulting from the
simultaneous activation of these two presynaptic neuro-
modulatory systems, we also studied the effect of the
co-activation of A2A and mGluR5 receptors, but now with
maximally effective concentrations of each agonist. Under
these conditions, one would expect that physically interact-
ing receptors should produce a less than additive effect,
because only one rather than two G proteins can bind the
complex at a time (e.g. Breitwieser 2004) levelling the
agonist efficacy to that of the most efficacious individual
receptor system (Kenakin 2002). In fact, as illustrated in
Fig. 5(d), the facilitation of glutamate release on co-
activation with maximally effective concentrations of A2A
and mGluR5 agonists was partially additive but not
synergistic. Thus, the co-administration of 10 nM
CGS 21680, together with 300 lM CHPG, caused a
72.7 ± 5.2% (n ¼ 6) facilitation. This facilitation is lower
than the sum of the facilitatory effects caused by 10 nM
CGS 21680 (57.1 ± 9.8%) or 300 lM CHPG (25.7 ± 6.4%)
when tested alone.
Discussion
The present results provide direct morphological and func-
tional evidence indicating that adenosine A2A receptors and
metabotropic glutamate receptors subtype 5 (mGluR5) are
co-located in a subset of glutamatergic nerve terminals of the
rat striatum. In fact, we found that there was a co-localization
of A2A and mGluR5 receptor immunoreactivity in striatal
nerve terminals and, in particular, in nerve terminals
endowed with the vesicular glutamate transporter type 1
or type 2 (vGluT1or vGluT2), i.e. glutamatergic nerve
A2A receptor
44 kDa
146 kDa
pre post extra synap
pre post extra synap
mGluR 5
95 kDa
PSD-95
35 kDa
Syntaxin
40 kDa
Synaptophysin
(a)
(b)
(c)
Fig. 3 Subsynaptic distribution of adenosine A2A receptors (a) and
metabotropic glutamate receptor subtype 5 (mGluR5) (b). The figures
correspond to a western blot comparing the A2A receptor (a) and
mGluR5 (b) immunoreactivity, corresponding to the 44-kDa (a) and
146-kDa (b) bands, in a fraction enriched in the presynaptic active
zone (pre), in the postsynaptic density (post), in nerve terminals out-
side the active zone (extra) and in the initial synaptosomal fraction
(synap) from where fractionation began. These fractions were over
90% pure, as illustrated by the ability to recover the immunoreactivity
for syntaxin in the presynaptic active zone fraction, PSD95 in the
postsynaptic density fraction and synaptophysin (a protein located in
synaptic vesicles) in the extra-synaptic fraction (c). Forty micrograms
of protein of each fraction was applied to the sodium dodecyl sulfate –
polyacrylamide gel electrophoresis (SDS–PAGE) gel. Each blot is
representative of four blots from different animals with similar results.
Note that, although both mGluR5 and A2A receptors are most abun-
dant in the postsynaptic density fraction, they are also located in the
active zone fraction.
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terminals. Furthermore, the activation of A2A or mGluR5
receptors facilitated the evoked release of glutamate from
superfused striatal nerve terminals, these effects being
prevented by selective antagonists of each receptor. The
strength of this main conclusion is reinforced by our choice
to use purified nerve terminals, which excludes the possible
involvement of indirect, circuit-mediated effects and allows
ascribing the observed effects as direct effects on glutamat-
ergic nerve terminals. It should be pointed out that, although
we are emphasising the novelty of the present finding that
A2A and mGluR5 receptors are located in glutamatergic
nerve terminals, we observed that the majority of each of
these receptors is located outside nerve terminals in striatal
tissue, namely in the postsynaptic density, in accordance
with previous reports (Hettinger et al. 2001; Paquet and
Smith 2003). This confirms the role of A2A and mGluR5
receptors in the control of the responsiveness of medial spiny
neurons (Ferre´ et al. 2002; Nishi et al. 2003). However, the
observation that there was a lower density of A2A and
mGluR5 receptors located in glutamatergic nerve terminals
does not necessarily mean that the modulation of glutamate
release by A2A and mGluR5 receptors might represent a
minor action of these receptors in the striatum. In fact, it
should be noted that the volume and amount of protein
associated with nerve terminals is expected to be several-fold
lower than other neuronal compartments like dendrites
(Rusakov et al. 1998; Itzev et al. 2001). Therefore, when
considering receptors that are located both pre- and postsy-
naptically, it is always expected that they should be more
abundant postsynaptically because of the larger volume
Fig. 4 Co-localization of adenosine A2A receptors and metabotropic
glutamate receptor subtype 5 (mGluR5) in glutamatergic nerve termi-
nals of the rat striatum. (a) The immunocytochemical identification of
adenosine A2A receptors and mGluR5 (left panels) in the total popula-
tion of rat striatal nerve terminals (identified as synaptophysin immu-
noreactive). Merged images (right panels) illustrate that about 45% of
striatal nerve terminals are endowed with A2A receptors and near 50%
are endowed with mGluR5. (b) The immunocytochemical identification
of adenosine A2A receptors (left panel) and mGluR5 receptors (centre
panel) and a merged image that illustrates the near complete (84–90%)
co-localization of these two receptors in striatal nerve terminals. (c) The
immunocytochemical identification of A2A receptors (left panel),
mGluR5 (right panel) and vesicular glutamate transporters type 1 and
type 2 (vGluT1 and vGluT2, markers of glutamatergic nerve terminals)
showing that there is a co-localization of mGluR5 and A2A receptors in
nearly 50% of the glutamatergic nerve terminals (identified as vGluT1
and vGluT2 immunoreactive). These fields are representative of three
different fields per cover-slip, in experiments carried out three to four
times using different synaptosomal preparations from different animals.
The data are mean ± SEM of three to four experiments.
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occupied by dendrites. Also, the population of nerve
terminals which are glutamatergic is low in the striatum
(20%), so the relative amount of A2A and mGluR5 receptors
associated with these particular subtypes of nerve terminals
actually represent a robust density of these receptors in
glutamatergic nerve terminals, given that only 50% of the
glutamatergic terminals are equipped with these receptors.
Finally, it should be stressed that glutamate is actually the
chief signal to drive rather than to modulate striatal circuits
(as occurs with postsynaptic metabotropic receptors) and any
modulatory effect on the release of glutamate is expected to
have profound consequences in the functioning of striatal
circuits.
Previous studies by others have documented the ability of
A2A receptor ligands to affect the outflow of glutamate in
the striatum (Corsi et al. 2000). However, these studies
were carried out using in vivo microdialysis and do not
allow us to distinguish between a direct control of
glutamate release and indirect effects as a result of the
change of firing of the circuitry controlling glutamate
release, as pointed out by the authors (Corsi et al. 2000,
2003). In fact, these studies observed that activation of A2A
receptors had an opposite effect on the spontaneous and K+-
evoked release of glutamate (Corsi et al. 2000), which
supports multiple superimposable mechanisms of control by
A2A receptors of glutamate release that do not allow us to
ascribe direct effects of A2A receptors on glutamatergic
nerve terminals. Likewise, it was also shown that activation
of mGluR5 receptors enhances striatal glutamate levels
(Pintor et al. 2000), but again it was not possible to define
whether these effects were indirectly circuit-mediated or
direct effects on glutamatergic terminals, an issue that is
still debatable in other brain regions (cf. Sistisaga et al.
1998; Reid et al. 1999). Thus, the present results allow us
to conclude that both adenosine A2A and mGluR5 receptors
are located in glutamatergic nerve terminals and their
activation facilitates the evoked release of glutamate in the
striatum.
This observed presynaptic localization and marked facil-
itatory effects of A2A and mGluR5 receptors in striatal
glutamatergic nerve terminals may be of relevance for our
understanding of the mechanisms by which antagonists of
either type of receptors acts as neuroprotective or anti-
Parkinsonian agents. In fact, imbalances in the amount of
released glutamate are a common cause of neurodegenera-
tion in a variety of acute or chronic noxious brain conditions
(Lipton and Rosenberg 1994). Also, because glutamate is
the signal that actually triggers, rather than modulates,
striatal circuits (Calabresi et al. 1996), any modulatory
effect on this chief signal is expected to have a stronger
impact on striatal circuitry. Either A2A receptor antagonists
(Schwarzschild et al. 2002) or mGluR5 receptor antagonists
(Ossowska et al. 2001) are currently being explored as
potential anti-parkinsonian drugs. The anti-parkinsonian
effects of these two types of antagonists has so far been
thought to result from their ability to control postsynaptic
responsiveness selectively in medial spiny neurons of the
indirect pathway (Ferre´ et al. 2003), which is hyperfunc-
tioning in Parkinson’s disease (Obeso et al. 2000). The
present observation that these two receptor systems are also
located in glutamatergic nerve terminals and enhance the
release of glutamate, which is actually the trigger of striatal
pathways, raises the hypothesis that the anti-parkinsonian
effects of these antagonists might also involve the attenu-
ation of the glutamatergic drive of striatal pathways. If A2A
and mGluR5 receptors would be located in glutamatergic
terminals impinging on medial spiny neurons of the direct
pathway, blockade of these facilitatory receptors would
contribute to decreasing the drive of this already depressed
pathway in situations of Parkinson’s disease, i.e. A2A and
mGluR5 antagonists would actually contribute to worsen the
balance of striatal circuitry, the opposite of that which is
experimentally observed (Ossowska et al. 2001; Schwarzs-
child et al. 2002). For the control of glutamate release by
A2A and mGluR5 receptors to make sense in the realm of
their anti-parkinsonian effects, one needs to assume the
hypothesis that these receptors would be located mostly in
the glutamatergic bouttons that trigger the indirect rather
than the direct pathway. It should be made clear that this is a
working hypothesis and that there is no experimental
evidence to support this hypothesis. However, there is a
proof of concept for the selective localization of a presy-
naptic neuromodulatory system (operated by ATP P2X2
receptors) only in synapses with particular targets within the
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Fig. 5 Interaction between the adenosine A2A receptor agonist,
CGS 21680, and the metabotropic glutamate receptor subtype 5
(mGluR5) agonist, CHPG, in the facilitation of the evoked release of
[3H]glutamate from rat striatal nerve terminals. *p < 0.05. The dashed
bar in (d) illustrates the arithmetic sum of the facilitatory effects of
10 nM CGS 21680 and 300 lM CHPG, if these effects were purely
additive. The results are mean ± SEM of four to six experiments.
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same neuron in hippocampal circuits (Khakh et al. 2003). It
is also striking that only half of the glutamatergic nerve
terminals in the striatum are equipped with A2A and
mGluR5 receptors. Further work based on electrophysio-
logical recordings of cortico-thalamic striatal excitatory
transmission will hopefully allow the testing of this current
hypothesis that A2A and mGluR5 receptors might only be
located in the glutamatergic nerve terminals that selectively
innervate medial spiny neurons of the indirect pathway
question.
Another issue that arises from the present results is the
interest of either A2A (Fredholm et al. 2003) or mGluR5
antagonists (Bruno et al. 2000; Battaglia et al. 2002) as
neuroprotective agents in different neurotoxic situations that
involve glutamatergic excitotoxicity. In light of the observed
cross-inhibitory effects of mGluR5 and A2A receptor antag-
onists now observed to occur in the control of glutamate
release, is would be interesting to test whether there is also a
lack of additivity in the neuroprotective effects of the
antagonists of these two modulatory systems. In fact, if there
is an additivity of protective effects caused by antagonists of
A2A and mGluR5 receptors, then one should search for sites
of action of these receptors systems other than the control of
glutamate release or the control of the responsiveness of the
indirect pathway. In contrast, if there is no additive protective
effects with the simultaneous administration of the antago-
nists of A2A and mGluR5 receptors, then one is faced with a
very favourable situation where a combined subdosage of
each antagonist could yield maximal neuroprotection, while
decreasing the eventual risk of side-effects because of each
receptor system operating in different brain regions or
organs. The same rationale should hold true for anti-
parkinsonian effects for which studies resulting from the
co-administration of A2A and mGluR5 antagonists are
warranted.
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